Publication at Faculty of Medicine in Hradec Králové |
2020
Abstract
Current treatment algorhitms for metastatic renal cell carcinoma are based on the sequential use of drugs. It is therefore to have prognostic and predictive markers available before starting treatment so that the right drug can be chosen for a particular patient with a particular type of kidney tumor.
The article discusses potential biomarkers.